Report Overview
Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.
The global Overactive Bladder (OAB) Therapeutics market size was estimated at USD 5100 million in 2023 and is projected to reach USD 6313.49 million by 2032, exhibiting a CAGR of 2.40% during the forecast period.
North America Overactive Bladder (OAB) Therapeutics market size was estimated at USD 1384.15 million in 2023, at a CAGR of 2.06% during the forecast period of 2025 through 2032.
This report provides a deep insight into the global Overactive Bladder (OAB) Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Overactive Bladder (OAB) Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Overactive Bladder (OAB) Therapeutics market in any manner.
Global Overactive Bladder (OAB) Therapeutics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries
Market Segmentation (by Type)
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Market Segmentation (by Application)
Hosptial
Clinci
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Overactive Bladder (OAB) Therapeutics Market
Overview of the regional outlook of the Overactive Bladder (OAB) Therapeutics Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the
major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Overactive Bladder (OAB) Therapeutics
1.2 Key Market Segments
1.2.1 Overactive Bladder (OAB) Therapeutics Segment by Type
1.2.2 Overactive Bladder (OAB) Therapeutics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Overactive Bladder (OAB) Therapeutics Market Overview
2.1 Global Market Overview
2.1.1 Global Overactive Bladder (OAB) Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Overactive Bladder (OAB) Therapeutics Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Overactive Bladder (OAB) Therapeutics Market Competitive Landscape
3.1 Global Overactive Bladder (OAB) Therapeutics Sales by Manufacturers (2019-2025)
3.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Manufacturers (2019-2025)
3.3 Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Overactive Bladder (OAB) Therapeutics Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Overactive Bladder (OAB) Therapeutics Sales Sites, Area Served, Product Type
3.6 Overactive Bladder (OAB) Therapeutics Market Competitive Situation and Trends
3.6.1 Overactive Bladder (OAB) Therapeutics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Overactive Bladder (OAB) Therapeutics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Overactive Bladder (OAB) Therapeutics Industry Chain Analysis
4.1 Overactive Bladder (OAB) Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Overactive Bladder (OAB) Therapeutics Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Overactive Bladder (OAB) Therapeutics Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2019-2025)
6.3 Global Overactive Bladder (OAB) Therapeutics Market Size Market Share by Type (2019-2025)
6.4 Global Overactive Bladder (OAB) Therapeutics Price by Type (2019-2025)
7 Overactive Bladder (OAB) Therapeutics Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Overactive Bladder (OAB) Therapeutics Market Sales by Application (2019-2025)
7.3 Global Overactive Bladder (OAB) Therapeutics Market Size (M USD) by Application (2019-2025)
7.4 Global Overactive Bladder (OAB) Therapeutics Sales Growth Rate by Application (2019-2025)
8 Overactive Bladder (OAB) Therapeutics Market Consumption by Region
8.1 Global Overactive Bladder (OAB) Therapeutics Sales by Region
8.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Region
8.1.2 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region
8.2 North America
8.2.1 North America Overactive Bladder (OAB) Therapeutics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Overactive Bladder (OAB) Therapeutics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Overactive Bladder (OAB) Therapeutics Market Production by Region
9.1 Global Production of Overactive Bladder (OAB) Therapeutics by Region (2019-2025)
9.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2019-2025)
9.3 Global Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Overactive Bladder (OAB) Therapeutics Production
9.4.1 North America Overactive Bladder (OAB) Therapeutics Production Growth Rate (2019-2025)
9.4.2 North America Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Overactive Bladder (OAB) Therapeutics Production
9.5.1 Europe Overactive Bladder (OAB) Therapeutics Production Growth Rate (2019-2025)
9.5.2 Europe Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Overactive Bladder (OAB) Therapeutics Production (2019-2025)
9.6.1 Japan Overactive Bladder (OAB) Therapeutics Production Growth Rate (2019-2025)
9.6.2 Japan Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Overactive Bladder (OAB) Therapeutics Production (2019-2025)
9.7.1 China Overactive Bladder (OAB) Therapeutics Production Growth Rate (2019-2025)
9.7.2 China Overactive Bladder (OAB) Therapeutics Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Allergan
10.1.1 Allergan Overactive Bladder (OAB) Therapeutics Basic Information
10.1.2 Allergan Overactive Bladder (OAB) Therapeutics Product Overview
10.1.3 Allergan Overactive Bladder (OAB) Therapeutics Product Market Performance
10.1.4 Allergan Business Overview
10.1.5 Allergan Overactive Bladder (OAB) Therapeutics SWOT Analysis
10.1.6 Allergan Recent Developments
10.2 Astellas Pharma
10.2.1 Astellas Pharma Overactive Bladder (OAB) Therapeutics Basic Information
10.2.2 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Overview
10.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Market Performance
10.2.4 Astellas Pharma Business Overview
10.2.5 Astellas Pharma Overactive Bladder (OAB) Therapeutics SWOT Analysis
10.2.6 Astellas Pharma Recent Developments
10.3 Hisamitsu Pharmaceutical
10.3.1 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Basic Information
10.3.2 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Overview
10.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Market Performance
10.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics SWOT Analysis
10.3.5 Hisamitsu Pharmaceutical Business Overview
10.3.6 Hisamitsu Pharmaceutical Recent Developments
10.4 Pfizer
10.4.1 Pfizer Overactive Bladder (OAB) Therapeutics Basic Information
10.4.2 Pfizer Overactive Bladder (OAB) Therapeutics Product Overview
10.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Product Market Performance
10.4.4 Pfizer Business Overview
10.4.5 Pfizer Recent Developments
10.5 Ferring
10.5.1 Ferring Overactive Bladder (OAB) Therapeutics Basic Information
10.5.2 Ferring Overactive Bladder (OAB) Therapeutics Product Overview
10.5.3 Ferring Overactive Bladder (OAB) Therapeutics Product Market Performance
10.5.4 Ferring Business Overview
10.5.5 Ferring Recent Developments
10.6 GlaxoSmithKline
10.6.1 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Basic Information
10.6.2 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Overview
10.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Market Performance
10.6.4 GlaxoSmithKline Business Overview
10.6.5 GlaxoSmithKline Recent Developments
10.7 Ion Channel Innovations
10.7.1 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Basic Information
10.7.2 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Overview
10.7.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Market Performance
10.7.4 Ion Channel Innovations Business Overview
10.7.5 Ion Channel Innovations Recent Developments
10.8 Kwang Dong Pharmaceutical
10.8.1 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Basic Information
10.8.2 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Overview
10.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Market Performance
10.8.4 Kwang Dong Pharmaceutical Business Overview
10.8.5 Kwang Dong Pharmaceutical Recent Developments
10.9 Lanzhou Institute of Biological Products
10.9.1 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Basic Information
10.9.2 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Overview
10.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Market Performance
10.9.4 Lanzhou Institute of Biological Products Business Overview
10.9.5 Lanzhou Institute of Biological Products Recent Developments
10.10 Merck
10.10.1 Merck Overactive Bladder (OAB) Therapeutics Basic Information
10.10.2 Merck Overactive Bladder (OAB) Therapeutics Product Overview
10.10.3 Merck Overactive Bladder (OAB) Therapeutics Product Market Performance
10.10.4 Merck Business Overview
10.10.5 Merck Recent Developments
10.11 ONO Pharmaceutical
10.11.1 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Basic Information
10.11.2 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Overview
10.11.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Market Performance
10.11.4 ONO Pharmaceutical Business Overview
10.11.5 ONO Pharmaceutical Recent Developments
10.12 Sanofi
10.12.1 Sanofi Overactive Bladder (OAB) Therapeutics Basic Information
10.12.2 Sanofi Overactive Bladder (OAB) Therapeutics Product Overview
10.12.3 Sanofi Overactive Bladder (OAB) Therapeutics Product Market Performance
10.12.4 Sanofi Business Overview
10.12.5 Sanofi Recent Developments
10.13 Tengion
10.13.1 Tengion Overactive Bladder (OAB) Therapeutics Basic Information
10.13.2 Tengion Overactive Bladder (OAB) Therapeutics Product Overview
10.13.3 Tengion Overactive Bladder (OAB) Therapeutics Product Market Performance
10.13.4 Tengion Business Overview
10.13.5 Tengion Recent Developments
10.14 Teva Pharmaceutical Industries
10.14.1 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Basic Information
10.14.2 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Overview
10.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Market Performance
10.14.4 Teva Pharmaceutical Industries Business Overview
10.14.5 Teva Pharmaceutical Industries Recent Developments
11 Overactive Bladder (OAB) Therapeutics Market Forecast by Region
11.1 Global Overactive Bladder (OAB) Therapeutics Market Size Forecast
11.2 Global Overactive Bladder (OAB) Therapeutics Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country
11.2.3 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Size Forecast by Region
11.2.4 South America Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Overactive Bladder (OAB) Therapeutics by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Overactive Bladder (OAB) Therapeutics Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Overactive Bladder (OAB) Therapeutics by Type (2025-2032)
12.1.2 Global Overactive Bladder (OAB) Therapeutics Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Overactive Bladder (OAB) Therapeutics by Type (2025-2032)
12.2 Global Overactive Bladder (OAB) Therapeutics Market Forecast by Application (2025-2032)
12.2.1 Global Overactive Bladder (OAB) Therapeutics Sales (K MT) Forecast by Application
12.2.2 Global Overactive Bladder (OAB) Therapeutics Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Overactive Bladder (OAB) Therapeutics Market Size Comparison by Region (M USD)
Table 5. Global Overactive Bladder (OAB) Therapeutics Sales (K MT) by Manufacturers (2019-2025)
Table 6. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Overactive Bladder (OAB) Therapeutics Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Overactive Bladder (OAB) Therapeutics as of 2022)
Table 10. Global Market Overactive Bladder (OAB) Therapeutics Average Price (USD/MT) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Overactive Bladder (OAB) Therapeutics Sales Sites and Area Served
Table 12. Manufacturers Overactive Bladder (OAB) Therapeutics Product Type
Table 13. Global Overactive Bladder (OAB) Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Overactive Bladder (OAB) Therapeutics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Overactive Bladder (OAB) Therapeutics Market Challenges
Table 22. Global Overactive Bladder (OAB) Therapeutics Sales by Type (K MT)
Table 23. Global Overactive Bladder (OAB) Therapeutics Market Size by Type (M USD)
Table 24. Global Overactive Bladder (OAB) Therapeutics Sales (K MT) by Type (2019-2025)
Table 25. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2019-2025)
Table 26. Global Overactive Bladder (OAB) Therapeutics Market Size (M USD) by Type (2019-2025)
Table 27. Global Overactive Bladder (OAB) Therapeutics Market Size Share by Type (2019-2025)
Table 28. Global Overactive Bladder (OAB) Therapeutics Price (USD/MT) by Type (2019-2025)
Table 29. Global Overactive Bladder (OAB) Therapeutics Sales (K MT) by Application
Table 30. Global Overactive Bladder (OAB) Therapeutics Market Size by Application
Table 31. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2019-2025) & (K MT)
Table 32. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2019-2025)
Table 33. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2019-2025) & (M USD)
Table 34. Global Overactive Bladder (OAB) Therapeutics Market Share by Application (2019-2025)
Table 35. Global Overactive Bladder (OAB) Therapeutics Sales Growth Rate by Application (2019-2025)
Table 36. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2019-2025) & (K MT)
Table 37. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2019-2025)
Table 38. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2019-2025) & (K MT)
Table 39. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2019-2025) & (K MT)
Table 40. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Region (2019-2025) & (K MT)
Table 41. South America Overactive Bladder (OAB) Therapeutics Sales by Country (2019-2025) & (K MT)
Table 42. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Region (2019-2025) & (K MT)
Table 43. Global Overactive Bladder (OAB) Therapeutics Production (K MT) by Region (2019-2025)
Table 44. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2019-2025)
Table 46. Global Overactive Bladder (OAB) Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 47. North America Overactive Bladder (OAB) Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 48. Europe Overactive Bladder (OAB) Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 49. Japan Overactive Bladder (OAB) Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 50. China Overactive Bladder (OAB) Therapeutics Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 51. Allergan Overactive Bladder (OAB) Therapeutics Basic Information
Table 52. Allergan Overactive Bladder (OAB) Therapeutics Product Overview
Table 53. Allergan Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 54. Allergan Business Overview
Table 55. Allergan Overactive Bladder (OAB) Therapeutics SWOT Analysis
Table 56. Allergan Recent Developments
Table 57. Astellas Pharma Overactive Bladder (OAB) Therapeutics Basic Information
Table 58. Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Overview
Table 59. Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 60. Astellas Pharma Business Overview
Table 61. Astellas Pharma Overactive Bladder (OAB) Therapeutics SWOT Analysis
Table 62. Astellas Pharma Recent Developments
Table 63. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Basic Information
Table 64. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Overview
Table 65. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 66. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics SWOT Analysis
Table 67. Hisamitsu Pharmaceutical Business Overview
Table 68. Hisamitsu Pharmaceutical Recent Developments
Table 69. Pfizer Overactive Bladder (OAB) Therapeutics Basic Information
Table 70. Pfizer Overactive Bladder (OAB) Therapeutics Product Overview
Table 71. Pfizer Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 72. Pfizer Business Overview
Table 73. Pfizer Recent Developments
Table 74. Ferring Overactive Bladder (OAB) Therapeutics Basic Information
Table 75. Ferring Overactive Bladder (OAB) Therapeutics Product Overview
Table 76. Ferring Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 77. Ferring Business Overview
Table 78. Ferring Recent Developments
Table 79. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Basic Information
Table 80. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Overview
Table 81. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 82. GlaxoSmithKline Business Overview
Table 83. GlaxoSmithKline Recent Developments
Table 84. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Basic Information
Table 85. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Overview
Table 86. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 87. Ion Channel Innovations Business Overview
Table 88. Ion Channel Innovations Recent Developments
Table 89. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Basic Information
Table 90. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Overview
Table 91. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 92. Kwang Dong Pharmaceutical Business Overview
Table 93. Kwang Dong Pharmaceutical Recent Developments
Table 94. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Basic Information
Table 95. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Overview
Table 96. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 97. Lanzhou Institute of Biological Products Business Overview
Table 98. Lanzhou Institute of Biological Products Recent Developments
Table 99. Merck Overactive Bladder (OAB) Therapeutics Basic Information
Table 100. Merck Overactive Bladder (OAB) Therapeutics Product Overview
Table 101. Merck Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 102. Merck Business Overview
Table 103. Merck Recent Developments
Table 104. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Basic Information
Table 105. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Overview
Table 106. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 107. ONO Pharmaceutical Business Overview
Table 108. ONO Pharmaceutical Recent Developments
Table 109. Sanofi Overactive Bladder (OAB) Therapeutics Basic Information
Table 110. Sanofi Overactive Bladder (OAB) Therapeutics Product Overview
Table 111. Sanofi Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 112. Sanofi Business Overview
Table 113. Sanofi Recent Developments
Table 114. Tengion Overactive Bladder (OAB) Therapeutics Basic Information
Table 115. Tengion Overactive Bladder (OAB) Therapeutics Product Overview
Table 116. Tengion Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 117. Tengion Business Overview
Table 118. Tengion Recent Developments
Table 119. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Basic Information
Table 120. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Overview
Table 121. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 122. Teva Pharmaceutical Industries Business Overview
Table 123. Teva Pharmaceutical Industries Recent Developments
Table 124. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Region (2025-2032) & (K MT)
Table 125. Global Overactive Bladder (OAB) Therapeutics Market Size Forecast by Region (2025-2032) & (M USD)
Table 126. North America Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
Table 127. North America Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 128. Europe Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
Table 129. Europe Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 130. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Forecast by Region (2025-2032) & (K MT)
Table 131. Asia Pacific Overactive Bladder (OAB) Therapeutics Market Size Forecast by Region (2025-2032) & (M USD)
Table 132. South America Overactive Bladder (OAB) Therapeutics Sales Forecast by Country (2025-2032) & (K MT)
Table 133. South America Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 134. Middle East and Africa Overactive Bladder (OAB) Therapeutics Consumption Forecast by Country (2025-2032) & (Units)
Table 135. Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Size Forecast by Country (2025-2032) & (M USD)
Table 136. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Type (2025-2032) & (K MT)
Table 137. Global Overactive Bladder (OAB) Therapeutics Market Size Forecast by Type (2025-2032) & (M USD)
Table 138. Global Overactive Bladder (OAB) Therapeutics Price Forecast by Type (2025-2032) & (USD/MT)
Table 139. Global Overactive Bladder (OAB) Therapeutics Sales (K MT) Forecast by Application (2025-2032)
Table 140. Global Overactive Bladder (OAB) Therapeutics Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Overactive Bladder (OAB) Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Overactive Bladder (OAB) Therapeutics Market Size (M USD), 2019-2032
Figure 5. Global Overactive Bladder (OAB) Therapeutics Market Size (M USD) (2019-2032)
Figure 6. Global Overactive Bladder (OAB) Therapeutics Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Overactive Bladder (OAB) Therapeutics Market Size by Country (M USD)
Figure 11. Overactive Bladder (OAB) Therapeutics Sales Share by Manufacturers in 2023
Figure 12. Global Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers in 2023
Figure 13. Overactive Bladder (OAB) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Overactive Bladder (OAB) Therapeutics Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Overactive Bladder (OAB) Therapeutics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Overactive Bladder (OAB) Therapeutics Market Share by Type
Figure 18. Sales Market Share of Overactive Bladder (OAB) Therapeutics by Type (2019-2025)
Figure 19. Sales Market Share of Overactive Bladder (OAB) Therapeutics by Type in 2023
Figure 20. Market Size Share of Overactive Bladder (OAB) Therapeutics by Type (2019-2025)
Figure 21. Market Size Market Share of Overactive Bladder (OAB) Therapeutics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Overactive Bladder (OAB) Therapeutics Market Share by Application
Figure 24. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2019-2025)
Figure 25. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application in 2023
Figure 26. Global Overactive Bladder (OAB) Therapeutics Market Share by Application (2019-2025)
Figure 27. Global Overactive Bladder (OAB) Therapeutics Market Share by Application in 2023
Figure 28. Global Overactive Bladder (OAB) Therapeutics Sales Growth Rate by Application (2019-2025)
Figure 29. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2019-2025)
Figure 30. North America Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 31. North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country in 2023
Figure 32. U.S. Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 33. Canada Overactive Bladder (OAB) Therapeutics Sales (K MT) and Growth Rate (2019-2025)
Figure 34. Mexico Overactive Bladder (OAB) Therapeutics Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 36. Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Country in 2023
Figure 37. Germany Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 38. France Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 39. U.K. Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 40. Italy Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 41. Russia Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 42. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Region in 2023
Figure 44. China Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 45. Japan Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 46. South Korea Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 47. India Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 48. Southeast Asia Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 49. South America Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (K MT)
Figure 50. South America Overactive Bladder (OAB) Therapeutics Sales Market Share by Country in 2023
Figure 51. Brazil Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 52. Argentina Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 53. Columbia Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 54. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 57. UAE Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 58. Egypt Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 59. Nigeria Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 60. South Africa Overactive Bladder (OAB) Therapeutics Sales and Growth Rate (2019-2025) & (K MT)
Figure 61. Global Overactive Bladder (OAB) Therapeutics Production Market Share by Region (2019-2025)
Figure 62. North America Overactive Bladder (OAB) Therapeutics Production (K MT) Growth Rate (2019-2025)
Figure 63. Europe Overactive Bladder (OAB) Therapeutics Production (K MT) Growth Rate (2019-2025)
Figure 64. Japan Overactive Bladder (OAB) Therapeutics Production (K MT) Growth Rate (2019-2025)
Figure 65. China Overactive Bladder (OAB) Therapeutics Production (K MT) Growth Rate (2019-2025)
Figure 66. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Overactive Bladder (OAB) Therapeutics Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Overactive Bladder (OAB) Therapeutics Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Overactive Bladder (OAB) Therapeutics Market Share Forecast by Type (2025-2032)
Figure 70. Global Overactive Bladder (OAB) Therapeutics Sales Forecast by Application (2025-2032)
Figure 71. Global Overactive Bladder (OAB) Therapeutics Market Share Forecast by Application (2025-2032)
